Nicholas Company Inc. Has $17.32 Million Position in STERIS plc (NYSE:STE)

by · The Cerbat Gem

Nicholas Company Inc. lowered its position in STERIS plc (NYSE:STEFree Report) by 0.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,254 shares of the medical equipment provider’s stock after selling 55 shares during the quarter. Nicholas Company Inc.’s holdings in STERIS were worth $17,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Avalon Trust Co acquired a new position in shares of STERIS in the fourth quarter valued at approximately $30,000. Human Investing LLC acquired a new position in shares of STERIS in the fourth quarter valued at approximately $31,000. Anfield Capital Management LLC increased its stake in shares of STERIS by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 91 shares during the period. Central Pacific Bank Trust Division increased its stake in shares of STERIS by 65.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 76 shares during the period. Finally, Manchester Capital Management LLC increased its stake in shares of STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 137 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on STE shares. Piper Sandler increased their target price on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Thursday, February 6th. Finally, Stephens reissued an “overweight” rating and set a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and a consensus target price of $258.75.

Read Our Latest Report on STERIS

STERIS Stock Performance

NYSE:STE opened at $227.04 on Friday. The company has a market capitalization of $22.31 billion, a PE ratio of 48.20 and a beta of 0.92. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The company has a 50 day simple moving average of $219.17 and a two-hundred day simple moving average of $222.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13.

STERIS (NYSE:STEGet Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s payout ratio is 48.41%.

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Read More

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).